ArticleMolecular biology reports2026
MiR-182 and MiR-34a regulate autophagy and apoptosis in tuberculosis and lung cancer.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer continues to be among the most fatal malignancies globally and exhibits a complex interplay with tuberculosis (TB). These conditions share several pathogenic pathways, notably involving apoptosis and autophagy, which play critical roles in disease progression and therapeutic responsiveness. MicroRNAs (miRNAs) function as pivotal post-transcriptional regulators, with miR-34a and miR-182 increasingly recognized as key modulators. Beyond their established roles in tumor development and host-pathogen interactions, these miRNAs influence diagnostic accuracy and therapeutic approaches in both lung cancer and TB
methodsTo investigate miRNA-driven regulatory mechanisms, A549 lung adenocarcinoma cells and THP-1 monocytic cells were transfected with vectors designed to overexpress miR-34a and miR-182. Apoptotic and autophagic processes were quantitatively assessed using high-resolution flow cytometry alongside functional validation assays. Additionally, the expression of key apoptotic and autophagy-related genes was analyzed to characterize downstream molecular effects resulting from miRNA modulation.
resultsQuantitative real-time PCR analysis demonstrated that miR-34a upregulated Bax while downregulating Bcl-2, leading to a pronounced increase in the Bax/Bcl-2 ratio. In contrast, miR-182 enhanced the expression of both Bax and Bcl-2, yet still facilitated apoptosis through an overall elevation of the Bax/Bcl-2 ratio. Within the autophagy-related signaling network, miR-34a exerted a suppressive effect on IL6, FOXO3, and TNFα expression, whereas miR-182 promoted the expression of genes associated with autophagic activity. These molecular findings were corroborated by flow cytometry, which revealed increased apoptotic activity accompanied by diminished autophagy. Collectively, the data indicate distinct yet complementary regulatory functions of miR-34a and miR-182 in determining cellular fate.
conclusionsmiR-34a and miR-182 exert significant regulatory effects on apoptotic and autophagic pathways in the context of lung cancer and tuberculosis. Their differentiated but coordinated actions highlight their potential utility as diagnostic biomarkers and therapeutic modulators. These findings suggest promising translational implications for the precision management of both infectious and malignant pulmonary disorders.
Indexed as
Identifiers
41739360What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.